Ambar Protein FY26 Results: Net profit falls 27% to ₹70.3 crore

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Revenue grew 18.7% YoY to ₹5,006.6 crore in FY26
  • Net profit fell 27.2% to ₹70.3 crore due to margin pressure
  • Inventories doubled to ₹386.7 crore; receivables halved to ₹101.8 crore
  • No dividend declared for the fiscal year ended March 31, 2026
  • AGM scheduled for September 30, 2026, to approve executive pay hikes
powered bylight_fuzz_icon
49732216

*this image is generated using AI for illustrative purposes only.

Ambar Protein Industries reported a 27.2% decline in net profit to ₹70.3 crore for the fiscal year ended March 31, 2026, despite revenue growing 18.7% to ₹5,006.6 crore. The edible oil manufacturer cited rising raw material costs and competitive pricing pressures as primary drivers for the contraction in profitability.

The company’s board of directors has convened the 33rd Annual General Meeting for September 30, 2026, to approve these financial statements. Shareholders will also vote on related-party transactions involving Ankur Oil Industries and variations in executive remuneration.

Financial Performance

Revenue from operations increased from ₹4,216.2 crore in FY25 to ₹5,006.6 crore in FY26. However, this top-line growth did not translate into bottom-line gains. Cost of raw materials consumed surged to ₹4,877.7 crore from ₹3,950.2 crore, outpacing revenue growth and compressing margins.

Metric FY26 FY25 Change
Revenue ₹5,006.6 crore ₹4,216.2 crore +18.7%
Net Profit ₹70.3 crore ₹96.5 crore -27.2%
Profit Before Tax ₹93.9 crore ₹130.3 crore -28.0%

Profit before tax fell 28.0% to ₹93.9 crore. Finance costs decreased slightly to ₹20.3 crore from ₹22.7 crore, providing minor support to overall profitability. Other income declined marginally to ₹78.1 lakh from ₹84.2 lakh.

What the Numbers Show

A significant divergence exists between revenue growth and profitability. While sales expanded by nearly 19%, net profit contracted by over 27%. This indicates that gross margins were severely impacted by input cost inflation, which rose faster than selling prices could adjust. The net profit margin compressed from 2.29% in FY25 to 1.40% in FY26.

Working Capital and Balance Sheet

Current assets rose to ₹592.2 crore from ₹483.4 crore, driven primarily by a sharp increase in inventories. Inventory levels more than doubled to ₹386.7 crore from ₹204.3 crore, reflecting higher raw material procurement and commodity price movements.

Conversely, trade receivables dropped significantly to ₹101.8 crore from ₹202.8 crore, indicating improved collection efficiency. The current ratio improved to 1.57 times from 1.45 times. Total borrowings remained stable at approximately ₹259.2 crore, while total equity grew to ₹417.7 crore due to retained earnings accumulation.

Corporate Governance and AGM

The company is seeking shareholder approval for several key resolutions at the upcoming AGM:

  • Reappointment of directors Bharat D Patel and Shirish D Patel, who retire by rotation.
  • Approval of remuneration for cost auditors J. B. Mistri & Co. at ₹40,000 for FY27.
  • Ratification of related-party transactions with Ankur Oil Industries, including leasing receipts of ₹1.0 crore and goods sales of ₹400.0 crore.
  • Variation in remuneration for Managing Director Pradeep C Khetani and Whole Time Director Jayprakash J Vachhani, allowing payments exceeding statutory limits if profits are inadequate.

No dividend was recommended for FY26 as the board prioritized resource conservation.

Historical Stock Returns for Ambar Protein Industries

1 Day5 Days1 Month6 Months1 Year5 Years
+2.58%-7.16%+23.69%+45.90%-13.31%0.0%

How might the doubling of inventory levels impact Ambar's working capital efficiency and cash flow in FY27 if commodity prices correct downwards?

What specific pricing strategies or hedging mechanisms will Ambar employ to pass on rising raw material costs to consumers without losing market share?

Will the approved variation in executive remuneration, allowing payments despite inadequate profits, signal a shift in corporate governance priorities for stakeholders?

Ambar Protein Industries
View Company Insights
View All News
like17
dislike

Ambar Protein Industries sets Sept 30 AGM for shareholder votes

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Ambar Protein Industries schedules 33rd AGM for September 30, 2026
  • Shareholders to approve ₹401 crore related-party transactions with Ankur Oil Industries
  • Remuneration variations proposed for MD and WTD exceeding statutory limits
  • Book closure dates set from September 24 to September 30, 2026
  • Company urges physical shareholders to update KYC and dematerialize holdings
powered bylight_fuzz_icon
49720080

*this image is generated using AI for illustrative purposes only.

Ambar Protein Industries Limited has scheduled its 33rd Annual General Meeting for September 30, 2026, at its registered office in Ahmedabad. The company confirmed the record date for voting eligibility as September 24, 2026.

The Ambar Protein Industries Board seeks shareholder consent for transactions totaling ₹401 crore with Ankur Oil Industries, alongside remuneration variations for the Managing Director and Whole Time Director. Shareholders are also reminded to update their KYC details and dematerialize physical securities as per SEBI regulations.

Key Agenda Items

The meeting will address both ordinary and special business items. Shareholders will vote on the adoption of financial statements for the year ended March 31, 2026, and the re-appointment of directors retiring by rotation.

Related-Party Transactions

The most material special business item involves approving related-party transactions under Section 188 of the Companies Act, 2013. The Company proposes to enter into the following arrangements with Ankur Oil Industries:

Transaction Type Amount (₹ crore)
Sale of goods 400.00
Leasing/sublease/rent 1.00
Disposal of machinery 1.50

These transactions involve common partners among the Company’s directors, including Mr. Pradeep C Khetani and Mr. Jayprakash J Vachhani. The Board states these deals are conducted on an arm’s length basis.

Management Remuneration

Shareholders will decide on varying the remuneration of two key executives:

  • Mr. Pradeep Chunilal Khetani (Managing Director): His current monthly draw is ₹1,75,000. The proposed variation allows his annual pay to exceed ₹1 crore or 5% of net profits, whichever is higher.
  • Mr. Jayprakash J Vachhani (Whole Time Director): Similarly, his remuneration may exceed statutory limits pending shareholder approval.

Additionally, the meeting will approve a commission for Non-Executive Director Mr. Bharatbhai D Patel at 1% of net profits for five years starting October 1, 2026.

Voting and Book Closure Details

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books will remain closed from Thursday, September 24, 2026 to Wednesday, September 30, 2026 (both days inclusive).

Remote e-voting begins on September 27, 2026, at 9:00 am and ends on September 30, 2026, at 5:00 pm. The cut-off date for e-voting is Wednesday, September 23, 2026.

Annual Report and Compliance Updates

The company has dispatched letters to members who have not registered their email addresses, providing web-links to access the Integrated Annual Report for FY26. The report is available on the company’s website under the investors section.

Shareholders holding physical securities are urged to update their KYC details, including PAN, address, bank account details, and nomination choices, pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37. Failure to update these details may result in payments being made only through electronic mode.

Historical Stock Returns for Ambar Protein Industries

1 Day5 Days1 Month6 Months1 Year5 Years
+2.58%-7.16%+23.69%+45.90%-13.31%0.0%

How might the approval of ₹401 crore in related-party transactions with Ankur Oil Industries impact Ambar Protein's future revenue stability and supply chain dependencies?

What are the potential implications for minority shareholders if the proposed remuneration structure for the Managing Director and Whole Time Director significantly increases executive compensation relative to net profits?

Could the significant increase in executive pay signal a shift in the company's growth strategy or performance expectations for FY27 and beyond?

Ambar Protein Industries
View Company Insights
View All News
like19
dislike

More News on Ambar Protein Industries

1 Year Returns:-13.31%